Edition:
India

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,676JPY
18 May 2018
Change (% chg)

¥0 (+0.00%)
Prev Close
¥1,676
Open
¥1,688
Day's High
¥1,688
Day's Low
¥1,674
Volume
6,799,500
Avg. Vol
7,872,678
52-wk High
¥1,688
52-wk Low
¥1,332

Latest Key Developments (Source: Significant Developments)

Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals
Thursday, 10 May 2018 

May 10(Reuters) - Astellas Pharma Inc <4503.T>:Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc <<>> for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe.Under the agreement, Astellas will have the exclusive right to research, develop, and commercialize rosiptor for all human diseases and conditions in Japan and additional countries in the Asia-Pacific region.  Full Article

Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan
Thursday, 10 May 2018 

May 9 (Reuters) - Astellas Pharma Inc <4503.T>::AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN.AQUINOX PHARMACEUTICALS SAYS AQUINOX TO RECEIVE $25 MILLION IN UPFRONT PAYMENT, POTENTIALLY OVER $100 MILLION IN ADDITIONAL MILESTONE PAYMENTS AND ROYALTIES.AQUINOX- ASTELLAS WILL HAVE EXCLUSIVE RIGHT TO RESEARCH, DEVELOP, COMMERCIALIZE ROSIPTOR FOR ALL HUMAN DISEASES AND CONDITIONS IN JAPAN, OTHER APAC COUNTRIES.  Full Article

FDA Approves Supplemental New Drug Application For Myrbetriq For Treatment Of Overactive Bladder Symptoms
Tuesday, 8 May 2018 

May 7 (Reuters) - Astellas Pharma Inc <4503.T>::FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR MYRBETRIQ® (MIRABEGRON) FOR USE IN COMBINATION WITH SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS.ASTELLAS PHARMA INC- SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) SUBMISSION WAS BASED ON DATA FROM GLOBAL PHASE 3 SYNERGY I, SYNERGY II AND BESIDE STUDIES.  Full Article

Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement
Monday, 23 Apr 2018 

April 23 (Reuters) - Astellas Pharma Inc <4503.T>::PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014.PROTEOSTASIS THERAPEUTICS SAYS AMENDMENT EXTENDS RESEARCH TERM FOR INITIAL PROJECT UNDER ASTELLAS AGREEMENT TO DEC 4, 2018 - SEC FILING.  Full Article

Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin
Monday, 26 Mar 2018 

March 26 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.SEATTLE GENETICS INC - COS ARE ALSO EVALUATING ENFORTUMAB VEDOTIN IN OTHER SOLID TUMORS, INCLUDING OVARIAN AND NON-SMALL CELL LUNG CARCINOMA.  Full Article

Astellas Pharma completes share repurchase
Monday, 26 Mar 2018 

March 26(Reuters) - Astellas Pharma Inc <4503.T>:Says it completes repurchase of 39.6 million shares of its common stock, for 60 billion yen in total, during period from Feb. 1 to March 23.  Full Article

Astellas Pharma says change of chairman and president
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - Astellas Pharma Inc <4503.T>:Says it appoints Yoshihiko Hatanaka as new chairman of the board, Kenji Yasukawa as new president and CEO, effective April 1 .  Full Article

Astellas Pharma fully acquires Mitobridge
Wednesday, 24 Jan 2018 

Jan 24(Reuters) - Astellas Pharma Inc <4503.T>:Says it fully acquired U.S.-based firm Mitobridge, Inc.  Full Article

Astellas Pharma says application of marketing approval for blinatumomab in Japan
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Astellas Pharma Inc <4503.T>:Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.In Japan, blinatumomab is jointly developed by Amgen Astellas BioPharma and the co.  Full Article

Astellas acquires Mitobridge under existing collaboration
Friday, 1 Dec 2017 

Nov 30 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS ACQUIRES MITOBRIDGE UNDER EXISTING COLLABORATION.SAYS ‍MITOBRIDGE WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF ASTELLAS FOLLOWING CLOSE OF ACQUISITION​.  Full Article

BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals

* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe